STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
213
13F, latest reported quarter
What the filings say about TAK
Insiders, 180 days
-$13.1M net sold
13 sellers · 10% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$4.3M
6 notices
Takeda Pharmaceutical insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, TAKEDA PHARMACEUTICAL CO LTD insiders sold a net $13.1M of stock across 20 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Foreign private issuer: most of its insiders are exempt from SEC Form 4, but some still file it; those filings are listed below, and the record may be incomplete.
1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Aug 10, 2026.
The trade is 18.0% of the 191,522 shares held after it.
2 other insiders sold within 30 days.
213 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Transformation Officer Duprey Lauren Rusckowski sold about $640.3K of TAK on Sep 14, 2026; 2 other insiders sold within 30 days and 213 funds added in the latest 13F quarter.
2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Aug 19, 2026.
The trade is 79.9% of the 145,465 shares held after it.
12 other insiders sold within 30 days.
213 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President, R&D Plump Andrew Stewart sold about $2.1M of TAK under a 10b5-1 plan on Sep 2, 2026; 12 other insiders sold within 30 days and 213 funds added in the latest 13F quarter.
1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Aug 10, 2026.
The trade is 7.5% of the 261,656 shares held after it.
12 other insiders sold within 30 days.
213 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President, R&D Plump Andrew Stewart sold about $363.3K of TAK under a 10b5-1 plan on Aug 19, 2026; 12 other insiders sold within 30 days and 213 funds added in the latest 13F quarter.
3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Aug 10, 2026.
The trade is 32.4% of the 40,049 shares held after it.
12 other insiders sold within 30 days.
213 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Human Resources Officer Greenway Nicola Deidre Petal sold about $235.1K of TAK on Aug 18, 2026; 12 other insiders sold within 30 days and 213 funds added in the latest 13F quarter.
1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Aug 10, 2026.
The trade is 30.3% of the 67,311 shares held after it.
12 other insiders sold within 30 days.
213 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Pres., Global Supply & Quality Shannon Elaine Mary sold about $357.4K of TAK on Aug 11, 2026; 12 other insiders sold within 30 days and 213 funds added in the latest 13F quarter.
20 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Nobody has filed for crossing 5%. That is a fact, not missing data.
TAK planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Lauren Rusckowski Duprey
Filed 2026-09-10
$634.4K
Plump Andrew Stewart
Filed 2026-09-02
$2.1M
Plump Andrew Stewart
Filed 2026-08-19
$363.3K
Nicola Greenway
Filed 2026-08-14
$225.7K
Elaine Shannon
Filed 2026-08-10
$355.3K
TAK mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Steward Values Enhanced International Fund
$12.2M position · as of 2026-07-31
3.6%
VanEck Pharmaceutical ETF
$25.3M position · as of 2026-06-30
2.9%
Catalyst/MAP Global Equity Fund
$2.7M position · as of 2026-06-30
2.8%
Catalyst/MAP Global Balanced Fund
$368.7K position · as of 2026-06-30
2.5%
AdvisorShares Dorsey Wright ADR ETF
$912.6K position · as of 2026-06-30
2.2%
SGI Global Equity Fund
$1.1M position · as of 2026-05-31
1.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $13.1M sold by insiders over 180 days, 213 funds added last quarter, $4.3M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
TAK ranks highest on risk and compliance (93rd percentile) and institutional and government (46th), and lowest on insider conviction (7th), among Pharma & Biotech peers.
Insider conviction
7
Inputs
Net Form 4 buying (codes P and S), 180d-$10.6M · 14 pct, sector of 428
Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
46
Inputs
Funds adding, latest quarter213 · 91 pct, sector of 698
Congress net buyers, 365dno Congress trades in 365 days
Federal contracts, 180dno federal contracts in 180 days
Lobbying spend, 4 quarters$20K · 2 pct, sector of 133
Risk and compliance
93
Inputs
Short interest, % of float+0.1% · 93 pct, sector of 813
Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
4 not measured: Profitability, Financial health, Growth, US patents
Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
Financial health needs 1 of 2 inputs, 0 present: no debt line filed
Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet
3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
TAK filings, in plain words
Are Takeda Pharmaceutical insiders buying or selling TAK?
In the 180 days to 2026-10-27, Takeda Pharmaceutical insiders were net sellers, a net $13.1M across purchases and sales reported on Form 4, by 13 sellers.
Are there planned insider sales of TAK?
Yes. 6 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $4.3M of stock; the latest, by Lauren Rusckowski Duprey, was filed 2026-09-10.
Read the full summary
In the 180 days to 2026-10-27, Takeda Pharmaceutical insiders were net sellers of TAK, a net $13.1M across purchases and sales reported on Form 4 by 13 sellers. 10% of the 20 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 6 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $4.3M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
No password to create and no card required. We store your email address, your watchlist and your preferences, nothing else.
PRIVACY & COOKIES
We track filings, not you.
Essential cookies keep you signed in and remember this choice.
Google Analytics 4 and Microsoft Clarity load only if you allow them here; they
count visits and record how pages are used. We run no advertising and never sell
data. Details in the privacy policy. Change this any time
via "Cookie settings" in the footer.
